MBIO Key Statistics, Chart & Performance
The current stock price of MBIO is 1.09 USD. In the past month the price decreased by -12.8%. In the past year, price decreased by -91.5%.
MBIO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.7 | 395.77B | ||
| AMGN | AMGEN INC | 15.1 | 177.79B | ||
| GILD | GILEAD SCIENCES INC | 14.82 | 150.57B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.98 | 118.84B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.25 | 81.61B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 796.86 | 53.69B | ||
| INSM | INSMED INC | N/A | 37.34B | ||
| NTRA | NATERA INC | N/A | 34.33B | ||
| BIIB | BIOGEN INC | 10.91 | 26.79B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.05 | 21.65B | ||
| INCY | INCYTE CORP | 16.61 | 20.94B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.29B |
Related stock screener links
About MBIO
Company Profile
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the translation of medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. The company is headquartered in Waltham, Massachusetts and currently employs 6 full-time employees. The company went IPO on 2017-08-22. The firm has partnered with medical institutions to advance the development of chimeric antigen receptor modified T cell (CAR T) therapies. Its pipeline is focused in two core areas: CAR T therapies for autoimmune diseases and hematologic malignancies and CAR T therapies for solid tumors. The company is developing a CAR T therapy for hematologic malignancies and autoimmune diseases in partnership with Fred Hutchinson Cancer Center targeting CD20 and for solid tumors in partnership with City of Hope National Medical Center targeting IL13Ra2. The company has also partnered with Nationwide Children’s Hospital for a herpes simplex virus type 1 oncolytic virus to enhance the activity of MB-101 for the treatment of patients with high-grade malignant brain tumors.
Company Info
MUSTANG BIO INC
95 Sawyer Rd, Suite 110
Waltham MASSACHUSETTS 01605 US
CEO: Manuel Litchman
Employees: 6
Phone: 17816524500
MUSTANG BIO INC / MBIO FAQ
What does MUSTANG BIO INC do?
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the translation of medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. The company is headquartered in Waltham, Massachusetts and currently employs 6 full-time employees. The company went IPO on 2017-08-22. The firm has partnered with medical institutions to advance the development of chimeric antigen receptor modified T cell (CAR T) therapies. Its pipeline is focused in two core areas: CAR T therapies for autoimmune diseases and hematologic malignancies and CAR T therapies for solid tumors. The company is developing a CAR T therapy for hematologic malignancies and autoimmune diseases in partnership with Fred Hutchinson Cancer Center targeting CD20 and for solid tumors in partnership with City of Hope National Medical Center targeting IL13Ra2. The company has also partnered with Nationwide Children’s Hospital for a herpes simplex virus type 1 oncolytic virus to enhance the activity of MB-101 for the treatment of patients with high-grade malignant brain tumors.
Can you provide the latest stock price for MUSTANG BIO INC?
The current stock price of MBIO is 1.09 USD. The price decreased by -1.8% in the last trading session.
What is the dividend status of MUSTANG BIO INC?
MBIO does not pay a dividend.
What is the ChartMill technical and fundamental rating of MBIO stock?
MBIO has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How many employees does MUSTANG BIO INC have?
MUSTANG BIO INC (MBIO) currently has 6 employees.
What is MUSTANG BIO INC worth?
MUSTANG BIO INC (MBIO) has a market capitalization of 7.96M USD. This makes MBIO a Nano Cap stock.
MBIO Technical Analysis
MBIO Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to MBIO. While MBIO seems to be doing ok healthwise, there are quite some concerns on its profitability.
MBIO Financial Highlights
Over the last trailing twelve months MBIO reported a non-GAAP Earnings per Share(EPS) of -1.26. The EPS increased by 98.53% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -12.06% | ||
| ROE | -23.9% | ||
| Debt/Equity | 0 |